CAR-T cell therapy's clinical potential remains constrained by a fundamental trafficking problem: these engineered immune cells tend to accumulate in the liver, spleen, and lungs rather than reaching tumor sites, limiting therapeutic efficacy while increasing toxicity risks. This misdirection occurs because macrophages in these organs recognize and consume the modified T cells before they can accomplish their anticancer mission.
Researchers have now demonstrated that coating CAR-T cells with red blood cell membrane-derived liposomes (Rlip) dramatically alters their biodistribution patterns. The coating presents CD47, a "don't eat me" signal that prevents macrophage phagocytosis, allowing the therapeutic cells to persist longer in circulation. In both leukemia and ovarian cancer models, Rlip-coated CAR-T cells showed markedly reduced accumulation in off-target organs while achieving enhanced tumor infiltration and superior therapeutic outcomes.
This biomimetic approach represents a significant advance in CAR-T optimization because it requires no genetic modifications—cells are simply incubated with the coating material. The strategy preserves the cells' natural phenotype, memory characteristics, and cytotoxic function while fundamentally changing their trafficking behavior. Unlike complex genetic engineering approaches that introduce safety uncertainties, this surface modification technique could be readily implemented in existing manufacturing workflows.
The findings address one of CAR-T therapy's most persistent challenges through elegant biological mimicry. By hijacking the immune system's own recognition mechanisms, this coating technology could potentially transform CAR-T biodistribution across multiple cancer types, making these powerful therapies more effective and safer for patients.